Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway

Table 1

Echocardiographic and fasting blood glucose data.

	CON	DCM	INS	LL	LM	LH
𝑛	4	4	4	7	8	8
FBG (mmol/L)	2.83±0.39	10.39±1.78^b	8.49±1.86^a	8.6±3.7^a	7.8±1.86^a	7.47±2.95^a
E/A	2.45±0.99	0.32±0.04^a	0.39±0.06^a	0.31±0.03^a	1.38±0.09^ad	0.35±0.1^a
EF	88.25±0.96	75.75±4.57^b	88.5±0.58	74.56±6.96^a	87.63±5.97^c	75.13±2.95^b
FS	52.25±0.96	44.5±2.52^b	53.25±0.5^d	39.33±8.46^b	52.13±3.76^d	38.88±2.3^b
LVPW (mm)	3.47±0.4	4.53±0.5^a	3.23±0.17^d	3.31±0.38^c	3.3±0.42^c	2.72±0.31^ad
LVEDD (mm)	5.54±0.99	6.54±0.35^a	6.27±0.68^a	5.47±0.59^c	4.88±0.76^ad	5.13±0.26^c

LVEDD: left ventricular end-diastolic diameter; LVPW: left ventricular posterior wall; E/A: the ratio of E and A (E: peak early transmitral filling velocity during early diastole; A: peak transmitral atrial filling velocity during late diastole); FS: fractional shortening; EF: ejection fraction; FBG: fasting blood glucose. ^a𝑃<0.05 versus CON rats; ^b𝑃<0.01 versus CON rats; ^c𝑃<0.05 versus DCM rats; ^d𝑃<0.01 versus DCM rats.